Brief: Palatin Issued Patent On Vyleesi For Hypoactive Sexual Desire Disorder In Patients With Controlled Hypertension
28/02/2023 13:53
Feb 28 (Reuters) - Palatin Technologies Inc PTN.A :
* PALATIN ISSUED PATENT ON VYLEESI® (BREMELANOTIDE
INJECTION) FOR
HYPOACTIVE SEXUAL DESIRE DISORDER IN PATIENTS WITH CONTROLLED
HYPERTENSION
Source text for Eikon: ID:nPn75vLGca
Further company coverage: PTN.A
Recent news on Palatin Technologies
See all newsPalatin Technologies Inc reports results for the quarter ended March 31 - Earnings Summary
Palatin Technologies Inc expected to post a loss of $1.20 a share - Earnings Preview
Palatin Technologies Q2 revenue rises yr/yr, net loss widens
Brief: Palatin Announces 1-For-50 Reverse Stock Split
Brief: Palatin Announces Positive Preclinical Efficacy Data For Oral MC4R Agonist PL7737 In Animal Model Of Obesity